anti-VEGF therapy

Using imaging to manage diabetic retinopathy
Using imaging to manage diabetic retinopathyCreating a partnership between the optometrists and retinal practices will enhance the care of patients and serve as a continuing source of education and reference for the OD community. This constant communication will help diabetic patients who are suffering from this multifactorial disease that affects their bodies. DR must be addressed from the optometrist’s point of view, retinal specialist’s point of view, and the primary-care physician’s point of view.
How to diagnose angioid streaks
How to diagnose angioid streaksAngioid streaks are a rare but potentially visually debilitating condition that present a unique challenge to the average eyecare provider. Learning to recognize its clinical presentation is just a start in an often difficult diagnosis to differentiate it from other similar retinal presentations. Ultimately understanding its association with a variety of systemic diseases is essential in successfully identifying and mitigating its link to vision loss.
Outcomes differ from trials with ‘real-world’ anti-VEGF therapy for DMEThe visual outcomes after anti-VEGF therapy administered to treat diabetic macular edema in the “real world” do not achieve those reported in randomized clinical trials. Eyes with better baseline visual acuity are disproportionately affected.
Povidone iodine reapplication: Protocol for preventing endophthalmitisTake-Home Message: A pearl for preventing endophthalmitis following intravitreal injections: avoid eyelid contact with the injection site after the last application of povidone iodine.
When diabetes goes from bad to worseA 30-year-old female with a 16-year history of insulin-dependent diabetes and no other ocular or systemic conditions developed proliferative retinopathy in March 2015. She had not been closely followed for the previous five years.
Novel therapies could stem burden of diabetic eye diseaseA better understanding of the pathophysiologic mechanisms of diabetes has resulted in improved control of its local and systemic comorbidities. Further developments are needed, however, considering the growing number of diabetic patients and who are at risk for late-stage diabetic eye disease.
Exploring sirolimus as potential alternative therapy for persistent AMDAnti-vascular endothelial growth factor (VEGF) therapy is highly successful, but as Raj Maturi, MD, pointed out, also has some limitations.
Priming syringe before injection associated with lower frequency of silicone oil dropletsAnother adverse effect associated with the compounding process of bevacizumab (Avastin, Genentech)—i.e., the presence of silicone oil droplets in the vitreous cavity—has surfaced within the past year and seems to be related to the preloading of the drug in insulin syringes.
Anti-angiogenic agent, platform planned for human trialFindings from preclinical studies show that a novel intravitreal depot of an anti-angiogenic drug releases the medication over a period of at least 6 months, is well-tolerated, and prevents VEGF-induced retinal vascular leakage.
Inhibition of PlGF shows additional features compared to VEGF inhibition
Inhibition of PlGF shows additional features compared to VEGF inhibitionAnti-vascular endothelial growth factor (VEGF) remains the gold standard therapy for diabetic retinopathy, but “when treating diabetic macular edema (DME), “about half of the patients treated with VEGF inhibitors do not respond to therapy,” said Tine Van Bergen, PhD, a scientist with ThromboGenics, Leuven, Belgium.